Sucroferric oxyhydroxide

Sucroferric oxyhydroxide is an iron-based phosphate binder used to control phosphorus levels in adults with chronic kidney disease (CKD) on dialysis. It is a non-calcium, non-aluminum phosphate binder that was approved by the Food and Drug Administration (FDA) in 2013.

Pharmacology

Sucroferric oxyhydroxide is a complex of iron(III)-oxyhydroxide, sucrose, and starches. It works by binding to dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and lowering serum phosphate levels in patients with CKD.

Clinical Use

Sucroferric oxyhydroxide is used to control serum phosphorus levels in patients with CKD on dialysis. High serum phosphorus levels, or hyperphosphatemia, is a common problem in patients with CKD and can lead to serious complications such as bone disease and cardiovascular disease.

Side Effects

The most common side effects of sucroferric oxyhydroxide include diarrhea, nausea, and vomiting. Other side effects may include constipation, abdominal pain, and hyperphosphatemia.

Dosage

The dosage of sucroferric oxyhydroxide is individualized based on the patient's serum phosphorus levels. The starting dose is usually 1.5 g/day, divided into three doses, taken with meals.

See Also

• Phosphate binders
• Chronic kidney disease
• Hyperphosphatemia